Management of infections due to KPC-producing Klebsiella pneumoniae

The emergence of the Klebsiella pneumoniae carbapenemases in K. pneumoniae and other Gram-negative bacteria, usually on a background of multidrug resistance, has led to difficult therapeutic choices. Among available antibiotics, tigecycline and the polymyxins are the most frequently active against t...

Descripción completa

Detalles Bibliográficos
Autores principales: Deresinski, Stanley C, Schirmer, Patricia
Formato: Texto
Lenguaje:English
Publicado: Medicine Reports Ltd 2009
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948324/
https://www.ncbi.nlm.nih.gov/pubmed/20948700
http://dx.doi.org/10.3410/M1-79
_version_ 1782187446663905280
author Deresinski, Stanley C
Schirmer, Patricia
author_facet Deresinski, Stanley C
Schirmer, Patricia
author_sort Deresinski, Stanley C
collection PubMed
description The emergence of the Klebsiella pneumoniae carbapenemases in K. pneumoniae and other Gram-negative bacteria, usually on a background of multidrug resistance, has led to difficult therapeutic choices. Among available antibiotics, tigecycline and the polymyxins are the most frequently active against these organisms in vitro. Optimal therapy of infections due to these bacteria may involve maximization of antibiotic dose as well as their use in combination.
format Text
id pubmed-2948324
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Medicine Reports Ltd
record_format MEDLINE/PubMed
spelling pubmed-29483242010-10-14 Management of infections due to KPC-producing Klebsiella pneumoniae Deresinski, Stanley C Schirmer, Patricia F1000 Med Rep Review Article The emergence of the Klebsiella pneumoniae carbapenemases in K. pneumoniae and other Gram-negative bacteria, usually on a background of multidrug resistance, has led to difficult therapeutic choices. Among available antibiotics, tigecycline and the polymyxins are the most frequently active against these organisms in vitro. Optimal therapy of infections due to these bacteria may involve maximization of antibiotic dose as well as their use in combination. Medicine Reports Ltd 2009-10-14 /pmc/articles/PMC2948324/ /pubmed/20948700 http://dx.doi.org/10.3410/M1-79 Text en © 2009 Medicine Reports Ltd http://creativecommons.org/licenses/by-nc/3.0/legalcode This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use this work for commercial purposes
spellingShingle Review Article
Deresinski, Stanley C
Schirmer, Patricia
Management of infections due to KPC-producing Klebsiella pneumoniae
title Management of infections due to KPC-producing Klebsiella pneumoniae
title_full Management of infections due to KPC-producing Klebsiella pneumoniae
title_fullStr Management of infections due to KPC-producing Klebsiella pneumoniae
title_full_unstemmed Management of infections due to KPC-producing Klebsiella pneumoniae
title_short Management of infections due to KPC-producing Klebsiella pneumoniae
title_sort management of infections due to kpc-producing klebsiella pneumoniae
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948324/
https://www.ncbi.nlm.nih.gov/pubmed/20948700
http://dx.doi.org/10.3410/M1-79
work_keys_str_mv AT deresinskistanleyc managementofinfectionsduetokpcproducingklebsiellapneumoniae
AT schirmerpatricia managementofinfectionsduetokpcproducingklebsiellapneumoniae

Ejemplares similares